FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3166351635> ?p ?o ?g. }

• W3166351635 endingPage "e16528" @default.
• W3166351635 startingPage "e16528" @default.
• W3166351635 abstract "e16528 Background: Immune checkpoint inhibitors (ICIs) targeting PD-1/L1 have been approved as first-line treatment for cisplatin-ineligible patients and as second-line therapy for patients with metastatic urothelial carcinoma of the bladder. Biomarkers can help select patients who are more likely to response to ICIs. RNF43 is an E3 ubiquitin ligase that acts as a negative regulator of Wnt/β-catenin signaling pathway. In colorectal cancer (CRC) patients treated with immune checkpoint inhibitors (ICIs), RNF43 mutations predicted longer overall survival (OS). The impact of RNF43 mutations on the efficiency of ICIs in bladder cancer(BLC) remains to be explored. Methods: We downloaded the mutation and clinical data of 211 BLC patients treated with ICIs from the immunotherapeutic cohort published by Samstein et al. (2019). OS analyses were conducted using Kaplan-Meier curves and log-rank tests. Wilcoxon test was used for the comparison of TMB. We also downloaded a TCGA cohort for prognostic analysis. The correlations between RNF43 and immune infiltrates were analyzed in the TIMER2.0 database. Statistical significance was set at p = 0.05. Results: RNF43 mutations were identified in 4.3%(9/211) and 3%(13/438) BLC patients in the immunotherapeutic and TCGA cohort, respectively. In the immunotherapeutic cohort, patients with RNF43 mutations had significantly longer OS (25 months vs 8 months; p = 0.015) and higher tumor mutation burden(TMB, 42.3 vs 7.9; p = 3.15E-06) than RNF43-wild-type patients. Different from this, no significant difference was found in OS between RNF43-mutant and RNF43-wild-type BLC patients with standard treatment in the TCGA cohort (p = 0.696). These results indicated that RNF43 was not a prognostic factor but a predictive biomarker of survival in BLC treated with ICIs. No difference was observed in subsets of immune cells between RNF43-mutant and the RNF43-wide-type BLC patients, including neutrophils, macrophages, CD8+ T cells, Tregs, B cells and NK cells. Conclusions: RNF43 mutations may be a predictor of survival benefit from ICIs in bladder cancer and correlated with higher TMB. Further studies in other ICI-treated cohorts are needed to confirm these results." @default.
• W3166351635 created "2021-06-22" @default.
• W3166351635 creator A5003815946 @default.
• W3166351635 creator A5038259858 @default.
• W3166351635 creator A5078275783 @default.
• W3166351635 date "2021-05-20" @default.
• W3166351635 modified "2023-09-23" @default.
• W3166351635 title "RNF43 mutations to predict survival from treatment with immune checkpoint inhibitors and are associated with a high tumor mutation burden in bladder cancer." @default.
• W3166351635 doi "https://doi.org/10.1200/jco.2021.39.15_suppl.e16528" @default.
• W3166351635 hasPublicationYear "2021" @default.
• W3166351635 type Work @default.
• W3166351635 sameAs 3166351635 @default.
• W3166351635 citedByCount "0" @default.
• W3166351635 crossrefType "journal-article" @default.
• W3166351635 hasAuthorship W3166351635A5003815946 @default.
• W3166351635 hasAuthorship W3166351635A5038259858 @default.
• W3166351635 hasAuthorship W3166351635A5078275783 @default.
• W3166351635 hasConcept C104317684 @default.
• W3166351635 hasConcept C121608353 @default.
• W3166351635 hasConcept C126322002 @default.
• W3166351635 hasConcept C143998085 @default.
• W3166351635 hasConcept C2777701055 @default.
• W3166351635 hasConcept C2780851360 @default.
• W3166351635 hasConcept C501734568 @default.
• W3166351635 hasConcept C526805850 @default.
• W3166351635 hasConcept C54355233 @default.
• W3166351635 hasConcept C71924100 @default.
• W3166351635 hasConcept C72563966 @default.
• W3166351635 hasConcept C86803240 @default.
• W3166351635 hasConceptScore W3166351635C104317684 @default.
• W3166351635 hasConceptScore W3166351635C121608353 @default.
• W3166351635 hasConceptScore W3166351635C126322002 @default.
• W3166351635 hasConceptScore W3166351635C143998085 @default.
• W3166351635 hasConceptScore W3166351635C2777701055 @default.
• W3166351635 hasConceptScore W3166351635C2780851360 @default.
• W3166351635 hasConceptScore W3166351635C501734568 @default.
• W3166351635 hasConceptScore W3166351635C526805850 @default.
• W3166351635 hasConceptScore W3166351635C54355233 @default.
• W3166351635 hasConceptScore W3166351635C71924100 @default.
• W3166351635 hasConceptScore W3166351635C72563966 @default.
• W3166351635 hasConceptScore W3166351635C86803240 @default.
• W3166351635 hasIssue "15_suppl" @default.
• W3166351635 hasLocation W31663516351 @default.
• W3166351635 hasOpenAccess W3166351635 @default.
• W3166351635 hasPrimaryLocation W31663516351 @default.
• W3166351635 hasRelatedWork W2042797183 @default.
• W3166351635 hasRelatedWork W2887848930 @default.
• W3166351635 hasRelatedWork W3184046266 @default.
• W3166351635 hasRelatedWork W3193396716 @default.
• W3166351635 hasRelatedWork W4281723870 @default.
• W3166351635 hasRelatedWork W4283823294 @default.
• W3166351635 hasRelatedWork W4289517314 @default.
• W3166351635 hasRelatedWork W4319002213 @default.
• W3166351635 hasRelatedWork W4323664831 @default.
• W3166351635 hasRelatedWork W4367313855 @default.
• W3166351635 hasVolume "39" @default.
• W3166351635 isParatext "false" @default.
• W3166351635 isRetracted "false" @default.
• W3166351635 magId "3166351635" @default.
• W3166351635 workType "article" @default.